Q3 2025 · 13F-HR
Novo Holdings A/Sholdings as filed
Filed 2025-11-14 · accession 0001388325-25-000025
$1.55B
Reported value
27
Positions
2025-09-30
Period end
The Brief · Novo Holdings A/S · Q3 2025
AI · grounded in 13F
Novo Holdings A/S established a new position in VTI valued at $340.8M. The fund also initiated new stakes in BN for $159.8M and ASML for $141.2M. Additional new positions include MIRM, EWTX, and CRM.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 922908769 | VTI | VANGUARD INDEX FDS | $340.8M | 22.0% | 1,038,550 | Common | SOLE |
| 11271J107 | BN | BROOKFIELD CORP | $159.8M | 10.3% | 2,330,830 | Common | SOLE |
| N07059210 | ASML | ASML HOLDING N V | $141.2M | 9.10% | 145,836 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $92.7M | 5.97% | 1,264,028 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $86.8M | 5.59% | 5,350,000 | Common | SOLE |
| 79466L302 | CRM | SALESFORCE INC | $78.3M | 5.04% | 330,187 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $70.6M | 4.55% | 750,000 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $67.7M | 4.36% | 1,625,000 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $51.4M | 3.31% | 2,380,000 | Common | SOLE |
| 01609W102 | BABA | ALIBABA GROUP HLDG LTD | $46.0M | 2.96% | 257,327 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $44.4M | 2.86% | 2,000,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $43.7M | 2.81% | 1,750,000 | Common | SOLE |
| 75629V104 | RXRX | RECURSION PHARMACEUTICALS IN | $38.7M | 2.49% | 7,929,835 | Common | SOLE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $35.8M | 2.31% | 1,942,142 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $35.7M | 2.30% | 660,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $33.0M | 2.13% | 916,160 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $31.0M | 2.00% | 1,200,000 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $29.2M | 1.88% | 1,426,260 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $28.8M | 1.86% | 200,000 | Common | SOLE |
| 92025Y103 | VALN | VALNEVA SE | $28.6M | 1.84% | 2,345,000 | Common | SOLE |
| 107924102 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $22.7M | 1.46% | 1,961,317 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $19.9M | 1.28% | 500,000 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $17.4M | 1.12% | 2,000,000 | Common | SOLE |
| 51655R200 | LNZA | LANZATECH GLOBAL INC | $3.9M | 0.25% | 158,148 | Common | SOLE |
| 57142B104 | MQ | MARQETA INC | $2.3M | 0.15% | 441,558 | Common | SOLE |
| 449778109 | IOBTQ | IO BIOTECH INC | $912,272 | 0.06% | 2,512,453 | Common | SOLE |
| 36322Q206 | DMRA | GALECTO INC | $322,074 | 0.02% | 86,579 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.